Jinyan Chen, Zhihang Hu, Huigang Li, Renyi Su, Zuyuan Lin, Jianyong Zhuo, Chiyu He, Ruijie Zhao, Wei Shen, Yajie You, Shuhan Jiang, Xuyong Wei, Shusen Zheng, Xiao Xu, Di Lu
{"title":"机器学习预测无肌肉减少的肝细胞癌患者移植后肌肉损失。","authors":"Jinyan Chen, Zhihang Hu, Huigang Li, Renyi Su, Zuyuan Lin, Jianyong Zhuo, Chiyu He, Ruijie Zhao, Wei Shen, Yajie You, Shuhan Jiang, Xuyong Wei, Shusen Zheng, Xiao Xu, Di Lu","doi":"10.1186/s12885-025-14973-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Developing a machine learning model to predict post-transplant muscle loss in hepatocellular carcinoma patients.</p><p><strong>Background: </strong>Liver transplantation is an effective treatment for selected HCC patients. However, severe muscle loss after liver transplantation is significantly associated with increased risk of mortality and recurrence. However, effective predictive methods remain inadequate.</p><p><strong>Methods: </strong>This study collected data from hepatocellular carcinoma patients who underwent liver transplantation over the past 2015 to 2020 at two hospitals. Propensity score matching and Cox regression analysis were conducted to establish muscle loss as an independent risk factor for recurrence. To construct the optimal predictive model for post-transplant muscle loss, we compared 50 machine learning models and use Recursive Feature Elimination to identify the most relative features.</p><p><strong>Results: </strong>Data from a total of 248 patients were collected. Kaplan-Meier analysis revealed a significant difference in prognosis between patients with and without sarcopenia before surgery. For patients without sarcopenia, postoperative muscle loss was identified as an independent risk factor for recurrence (HR = 2.38, P = 0.005). The best model was identified as the Imbalanced Random Forest, achieving an AUC of 0.832 on the non-sarcopenia cohort.</p><p><strong>Conclusions: </strong>A highly efficient model based on machine learning was developed to predict postoperative muscle loss in hepatocellular carcinoma patients undergoing liver transplantation, providing a valuable reference for the early detection of adverse events following the procedure.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1565"},"PeriodicalIF":3.4000,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12522249/pdf/","citationCount":"0","resultStr":"{\"title\":\"Machine learning predicts post-transplant muscle loss in hepatocellular carcinoma patients without sarcopenia.\",\"authors\":\"Jinyan Chen, Zhihang Hu, Huigang Li, Renyi Su, Zuyuan Lin, Jianyong Zhuo, Chiyu He, Ruijie Zhao, Wei Shen, Yajie You, Shuhan Jiang, Xuyong Wei, Shusen Zheng, Xiao Xu, Di Lu\",\"doi\":\"10.1186/s12885-025-14973-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Developing a machine learning model to predict post-transplant muscle loss in hepatocellular carcinoma patients.</p><p><strong>Background: </strong>Liver transplantation is an effective treatment for selected HCC patients. However, severe muscle loss after liver transplantation is significantly associated with increased risk of mortality and recurrence. However, effective predictive methods remain inadequate.</p><p><strong>Methods: </strong>This study collected data from hepatocellular carcinoma patients who underwent liver transplantation over the past 2015 to 2020 at two hospitals. Propensity score matching and Cox regression analysis were conducted to establish muscle loss as an independent risk factor for recurrence. To construct the optimal predictive model for post-transplant muscle loss, we compared 50 machine learning models and use Recursive Feature Elimination to identify the most relative features.</p><p><strong>Results: </strong>Data from a total of 248 patients were collected. Kaplan-Meier analysis revealed a significant difference in prognosis between patients with and without sarcopenia before surgery. For patients without sarcopenia, postoperative muscle loss was identified as an independent risk factor for recurrence (HR = 2.38, P = 0.005). The best model was identified as the Imbalanced Random Forest, achieving an AUC of 0.832 on the non-sarcopenia cohort.</p><p><strong>Conclusions: </strong>A highly efficient model based on machine learning was developed to predict postoperative muscle loss in hepatocellular carcinoma patients undergoing liver transplantation, providing a valuable reference for the early detection of adverse events following the procedure.</p>\",\"PeriodicalId\":9131,\"journal\":{\"name\":\"BMC Cancer\",\"volume\":\"25 1\",\"pages\":\"1565\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-10-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12522249/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12885-025-14973-5\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-14973-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:建立预测肝癌患者移植后肌肉损失的机器学习模型。背景:肝移植是肝癌患者的有效治疗方法。然而,肝移植后严重的肌肉损失与死亡率和复发风险增加显著相关。然而,有效的预测方法仍然不足。方法:本研究收集了两家医院2015年至2020年接受肝移植的肝细胞癌患者的数据。进行倾向评分匹配和Cox回归分析,以确定肌肉损失是复发的独立危险因素。为了构建移植后肌肉损失的最佳预测模型,我们比较了50个机器学习模型,并使用递归特征消除来识别最相关的特征。结果:共收集248例患者资料。Kaplan-Meier分析显示术前肌少症患者与非肌少症患者预后有显著差异。对于没有肌肉减少症的患者,术后肌肉损失被认为是复发的独立危险因素(HR = 2.38, P = 0.005)。最佳模型被确定为失衡随机森林,在非肌肉减少症队列上实现了0.832的AUC。结论:建立了一种高效的基于机器学习的肝癌肝移植术后肌肉损失预测模型,为术后不良事件的早期发现提供了有价值的参考。
Machine learning predicts post-transplant muscle loss in hepatocellular carcinoma patients without sarcopenia.
Objective: Developing a machine learning model to predict post-transplant muscle loss in hepatocellular carcinoma patients.
Background: Liver transplantation is an effective treatment for selected HCC patients. However, severe muscle loss after liver transplantation is significantly associated with increased risk of mortality and recurrence. However, effective predictive methods remain inadequate.
Methods: This study collected data from hepatocellular carcinoma patients who underwent liver transplantation over the past 2015 to 2020 at two hospitals. Propensity score matching and Cox regression analysis were conducted to establish muscle loss as an independent risk factor for recurrence. To construct the optimal predictive model for post-transplant muscle loss, we compared 50 machine learning models and use Recursive Feature Elimination to identify the most relative features.
Results: Data from a total of 248 patients were collected. Kaplan-Meier analysis revealed a significant difference in prognosis between patients with and without sarcopenia before surgery. For patients without sarcopenia, postoperative muscle loss was identified as an independent risk factor for recurrence (HR = 2.38, P = 0.005). The best model was identified as the Imbalanced Random Forest, achieving an AUC of 0.832 on the non-sarcopenia cohort.
Conclusions: A highly efficient model based on machine learning was developed to predict postoperative muscle loss in hepatocellular carcinoma patients undergoing liver transplantation, providing a valuable reference for the early detection of adverse events following the procedure.
期刊介绍:
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.